The explainable CoxBoost + StepCox framework demonstrated high prognostic accuracy (C-index = 0.955) in a limited cohort of rel/ref DLBCL patients receiving ibrutinib plus R-ICE, and CD5 + expression, initial response, time to relapse > 12 months, and elevated LDH as independent prognostic biomarkers. The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.